GRANULES.NS Stock Analysis
GR
Avoid
Based on Eyestock quantitative analysis, GRANULES.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 3,650 full-time employees. The firm operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The firm has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The firm sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Company’s wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.